
## iShares Genomics Immunology and Healthcare ETF (Fri, Apr 26, 2024)

Sell candidate since Apr 26, 2024



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

score: **-2.01** 

#13330/30083

Trend:	Sel
MV Long:	Sel
MV Short:	Buy
Pivot:	Buy
Volume:	Buy
MACD:	Sel

## **Tech commentaries:**

The **iShares Genomics Immunology and** ETF price gained **1.64%** on the last trading day (Friday, 26th Apr 2024), rising from **\$21.94** to **\$22.30**. During the last trading day the ETF fluctuated **1.87%** from a day low at **\$21.96** to a day high of **\$22.37**. The price has fallen in 7 of the last 10 days and is down by **-1.76%** for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **3 thousand** more shares were traded than the day before. In total, **18** thousand shares were bought and sold for approximately **\$396.36** thousand.

The ETF lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the ETF is expected to fall **-2.38%** during the next 3 months and, with a 90% probability hold a price between **\$21.15** and **\$24.20** at the end of this 3-month period.

A buy signal was issued from a pivot bottom point on **Friday, April 19, 2024**, and so far it has risen 2.72%. Further rise is indicated until a new top pivot has been found. **iShares Genomics Immunology and** has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **iShares Genomics Immunology and** ETF holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the long-term average is above the short-term average there is a general sell signal in the ETF giving a more negative forecast for the stock. On further gains, the ETF will meet resistance from the long-term Moving Average at \$23.26. On a fall, the ETF will find some support from the short-term average at \$22.04. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

**iShares Genomics Immunology and** finds support from accumulated volume at \$22.29 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the ETF meets some resistance just above today's level from accumulated volume at **\$22.53**, **\$23.75** and **\$24.05**.

This ETF has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the ETF moved **\$0.410** between high and low, or **1.87%**. For the last week, the ETF has had daily average volatility of **1.82%**.

**iShares Genomics Immunology and** holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this ETF. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this ETF since the last evaluation from a Hold/Accumulate to a Sell candidate.

Risk: Medium

Evaluation: Call Candidate